Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
NET REVENUE
Clinical testing	$ 59,791	$ 56,316	$ 116,482	$ 110,936
Pharma Services	6,299	6,813	11,285	11,896
Total Revenue	66,090	63,129	127,767	122,832
COST OF REVENUE	34,912	34,524	69,393	67,055
GROSS PROFIT	31,178	28,605	58,374	55,777
Operating expenses:
General and administrative	22,675	18,779	43,476	36,785
Research and development	947	1,306	1,809	2,752
Sales and marketing	6,242	6,327	11,890	12,127
Total operating expenses	29,864	26,412	57,175	51,664
INCOME FROM OPERATIONS	1,314	2,193	1,199	4,113
Interest expense, net	1,411	1,448	2,775	3,040
Income (loss) before taxes	(97)	745	(1,576)	1,073
Income tax (benefit) expense	(54)	332	(879)	505
NET INCOME (LOSS)	(43)	413	(697)	568
Deemed dividends on preferred stock	929	1,840	1,822	3,680
Amortization of preferred stock beneficial conversion feature	1,710	3,727	3,383	7,453
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (2,682)	$ (5,154)	$ (5,902)	$ (10,565)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.03)	$ (0.07)	$ (0.07)	$ (0.14)
Diluted	$ (0.03)	$ (0.07)	$ (0.07)	$ (0.14)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	79,413	77,448	79,075	76,758
Diluted	79,413	77,448	79,075	76,758